Australian Patent Granted for GaRP Product, Boosting Commercial Prospects.

Anatara Lifesciences (ASX: ANR) has secured an Australian patent for its Gastrointestinal ReProgramming (GaRP) product, titled "Gastrointestinal Health Composition." This patent, valid until October 2040, follows a similar European Union grant in 2024 and further strengthens the intellectual property (IP) protection for GaRP. The innovative product aims to restore gastrointestinal tract health and has potential applications beyond irritable bowel syndrome (IBS). The commercial market for non-prescription gastrointestinal disorder products is estimated at US$8 billion in the US alone.

The ongoing Phase II GaRP-IBS trial, now in Stage 2 with 71 participants, seeks to validate the product's efficacy, building on Stage 1 results that showed a greater than 50% reduction in IBS symptoms. Anatara’s Executive Chair, Dr. David Brookes, emphasized the patent's role in consolidating GaRP's market potential. Headline results from the trial are expected in March 2025, potentially advancing commercialization efforts.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com